The Journey of an FDA-Approved CDx for Rare Fusions: Rozlytrek CDx Case Study
- Genentech’s first FDA-approved tumor-agnostic medicine designed to target both ROS1 and NTRK
- Roche/Genentech and Foundation Medicine (FMI) CDx collaboration: Comprehensive genomic testing is critical to identify patients with rare gene fusions
- Understanding of the techniques for NTRK testing in clinical practice